The Human BioMolecular Research Institute (HBRI) is a 501(c)3 tax-exempt non-profit research institute doing basic research for the public good. HBRI was founded in December of 1997. The institute is located in the heart of biotech beach in a state-of-the-art 7,000 sq. ft. facility.
The research programs at HBRI are focused on unlocking biological and chemical principles related to diseases of the human body. Included in the areas of study are the use of stem cells to usher in new approaches to regenerative medicines for cardiovascular disease, neurological disease, cancer and bone diseases. Previous studies in Alzheimer’s disease and related neurodegenerative disorders, Parkinson’s disease, ALS, depression, neuroprotection, drug and alcohol abuse, pain and smoking cessation has resulted in numerous advances in medications development. The institute conducts fundamental studies of human disorders and translates findings into new drug development to address human illness. In addition, the institute promotes scientific learning through community service and public access by disseminating information and sharing research with collaborators, colleagues and the public.
“Where Medications Begin”
BREAKING NEWS: A Way to Safer New Drugs.
San Diego, Calif., October 2017 –Medicinal chemists and biologists at the Human BioMolecular Research Institute (HBRI), in San Diego, CA, and Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI), in San Diego, CA, respectively, have reported on a technology to monitor action potential (AP) kinetics and arrhythmia phenotypes in human cardiomyocytes in a high throughput manner in vitro. This may have importance for heart disease and other drug discovery efforts.
“We believe that the technology will lead to compounds that prove potent in vitro and efficacious in clinical trials, at lower doses, resulting in greater patient tolerance, and less side effects”… explains co-author Dr. John Cashman. “As drug development progresses, and less toxic drugs become available, patients will benefit from improved safety, possibly with significant cost-savings.”